



ASX Announcement

28 June 2017

Release of Escrowed Securities

In accordance with ASX Listing Rule 3.10.A, Creso Pharma Limited (ASX: CPH) advises that the following securities are due to be released from escrow:

| Description | Number | Date of Release |
|----------------------------|----------------|-----------------|
| Fully Paid Ordinary Shares | 712,500 | 14 July 2017 |
| Fully Paid Ordinary Shares | 135,000 | 18 July 2017 |
| Total | 847,500 | |

---END---

Investor Enquiries:

Gabriella Hold
M: 0411 364 382
E: gabriella.hold@mcpartners.com.au

Media Enquiries:

Harrison Polites
M: 0409 623 618
E: harrison.polites@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 0000

About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.